Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -471.98% is 354% below its 5-year average of -103.97%, near the low end of its 5-year range (-471.98%–-34.85%).
As of the fiscal period ended Tuesday, June 30, 2026. 75.27% below its 12-month average of -269.28%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -471.98%.
RETURN ON EQUITY (ROE)
-471.98%
RETURN ON EQUITY (ROE) AVG TTM
-269.28%
RETURN ON EQUITY (ROE) AVG 3Y
-134.25%
RETURN ON EQUITY (ROE) AVG 5Y
-103.97%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-75.27%
CURRENT VS 3Y AVG
-251.56%
CURRENT VS 5Y AVG
-353.96%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.15%
median of 730 covered companies
CURRENT VS SECTOR MEDIAN
-1046.98%
vs the sector median at left
Prime Medicine, Inc.
Market Cap
$628.48M
Return on Equity (ROE)
-471.98%
TTM Avg
-269.28%
3Y Avg
-134.25%
5Y Avg
-103.97%
Market Cap
$634.67M
Return on Equity (ROE)
-97.31%
TTM Avg
-116.17%
3Y Avg
-82.05%
5Y Avg
-65.68%
Market Cap
$634.26M
Return on Equity (ROE)
-41.56%
TTM Avg
-67.38%
3Y Avg
-49.66%
5Y Avg
-56.07%
Market Cap
$638.60M
Return on Equity (ROE)
-17.01%
TTM Avg
-22.91%
3Y Avg
-17.12%
5Y Avg
-14.58%
Market Cap
$617.19M
Return on Equity (ROE)
-24.06%
TTM Avg
-36.09%
3Y Avg
-34.99%
5Y Avg
-44.03%
Market Cap
$600.01M
Return on Equity (ROE)
N/A
TTM Avg
-4.73%
3Y Avg
76.70%
5Y Avg
93.92%
Market Cap
$657.39M
Return on Equity (ROE)
N/A
TTM Avg
385.53%
3Y Avg
385.53%
5Y Avg
385.53%
Market Cap
$592.60M
Return on Equity (ROE)
-21.51%
TTM Avg
-20.05%
3Y Avg
-35.91%
5Y Avg
-26.18%
Market Cap
$667.31M
Return on Equity (ROE)
-43.95%
TTM Avg
-29.61%
3Y Avg
-34.61%
5Y Avg
-30.48%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | $628.48M | -471.98% | -269.28% | -134.25% | -103.97% |
| SOPHiA GENETICS S.A. (SOPH)vs › | $634.67M | -97.31% | -116.17% | -82.05% | -65.68% |
| Aura Biosciences, Inc. (AURA)vs › | $634.26M | -41.56% | -67.38% | -49.66% | -56.07% |
| OmniAb, Inc. (OABI)vs › | $638.60M | -17.01% | -22.91% | -17.12% | -14.58% |
| Climb Bio, Inc. (CLYM)vs › | $617.19M | -24.06% | -36.09% | -34.99% | -44.03% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.01M | N/A | -4.73% | 76.70% | 93.92% |
| Starling Oncology, Inc. (STLN)vs › | $657.39M | N/A | 385.53% | 385.53% | 385.53% |
| AngioDynamics, Inc. (ANGO)vs › | $592.60M | -21.51% | -20.05% | -35.91% | -26.18% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $667.31M | -43.95% | -29.61% | -34.61% | -30.48% |
| Annexon, Inc. (ANNX)vs › | $664.82M | -108.93% | -72.41% | -64.95% | -55.74% |
ROE
-472.0%
ROA
-75.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -471.98% |
| 2026-03-31 | -258.64% |
| 2025-12-31 | -166.41% |
| 2025-09-30 | -121.95% |
| 2025-06-30 | -327.43% |
| 2025-03-31 | -188.93% |
| 2024-12-31 | -127.90% |
| 2024-09-30 | -115.70% |
| 2024-06-30 | -110.61% |
| 2024-03-31 | -83.89% |
| 2023-12-31 | -148.89% |
| 2023-09-30 | -88.56% |
| 2023-06-30 | -65.30% |
| 2023-03-31 | -51.56% |
| 2022-12-31 | -40.53% |
| 2022-09-30 | -87.90% |
| 2022-06-30 | -66.01% |
| 2022-03-31 | -44.81% |
| 2021-12-31 | -69.03% |
| 2021-09-30 | -34.85% |
